Product Images Uroxatral

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Uroxatral NDC 59212-200 by Concordia Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

bottle 100tablets

bottle 100tablets

This appears to be a label for a medication called "alfuzosin HCl" with a strength of 10 milligrams. The medication is made by a company called Concordia, and the brand name is Uroxatral. The label warns against chewing or crushing the tablets and advises swallowing them whole. It also includes an NDC code of 59212-200-10, a unique identifier for drugs. There is no other useful information provided.*

bottle 30tablets

bottle 30tablets

This is a description for a medication named Uroxatral, containing alfuzosin HCl 10mg. The medication is supplied in a bottle of 30 tablets that should be swallowed whole and not chewed or crushed. The package insert should be consulted for dosage information, and the medication should be stored in a dry and cool place away from kids. The NDC number for this medication is 59212-200-30.*

Chemical Structure - image 01

Chemical Structure - image 01

Figure 1 - image 02

Figure 1 - image 02

Figure 2 - image 03

Figure 2 - image 03

This text appears to be a graph or chart showing the mean change in some variable over time (28, 56, and 8 days) for two groups: a placebo group with 167 participants and a group treated with a medication called Uroxatral with 170 participants. The numbers likely correspond to the amount of change observed in the variable. However, without additional information, the meaning of the variable and the significance of the results cannot be determined.*

Figure 3 - image 04

Figure 3 - image 04

The text describes the mean change observed in two groups of individuals during 28 days of treatment with a placebo and Uroxatral. The treatment resulted in a significant difference between the two groups (p<0.01).*

Figure 4 - image 05

Figure 4 - image 05

Figure 5 - image 06

Figure 5 - image 06

Figure 6 - image 07

Figure 6 - image 07

Figure 7 - image 08

Figure 7 - image 08

The data table shows the mean change in mL/s for a treatment group (UROXATRAL) compared to a placebo group over a period of 8 days. The treatment group showed a decrease of 4 mL/s, but this change was not statistically significant (p>0.05) compared to the placebo group.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.